Breast Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Breast cancer therapeutics Market
The breast cancer therapeutics market size was valued at USD 21.58 billion in 2019, and the market is now projected to grow to USD 55.27 billion by 2027, exhibiting a CAGR of 13.1% during the forecast period of 2020-2027.
The COVID19 pandemic would have several cross effects on the pharmaceutical sector both positively and negatively. Many governments throughout the world used the complete nationwide lockdown measure in the early stages of the pandemic to contain the virus infections. This has resulted in health care industry experiencing some severe negative effects since the traffic to treatment centers was significantly cut. This hindered the breast cancer therapeutics market growth.
The most compelling force contributing to the development of the international market is the rising rates of breast cancer worldwide and the subsequently created need for a greater number of effective and precise diagnostic services. Breast cancer is one of the most common types of cancer and better diagnostic tools also mean that more people will be diagnosed with the disease. This factor drives the breast cancer therapeutics market share.
Among all the tendencies observed in the global market one of the most typical is the continuous research and development processes concerning the discovery and promotion of effective treatment for breast cancer. With an escalating number of affected global breast cancer patients, it is impossible to overstate the significance and the dire necessity of further innovating various effective treatments for the better prognoses.
Comprehensive Analysis of Breast cancer therapeutics Market
The breast cancer therapeutics market is responding quite an unprecedented rate of growth because of its market segmentation. This indicators growth in different regions by substituting the major forces of supply and demand which define the shape of local pharmacy benefit management market. Therefore, they are logically divided into 3 Segments, By Therapy Analysis, By Cancer Type Analysis and By Distribution Channel Analysis. Based on therapy, this market has targeted therapy, hormonal therapy, chemotherapeutic agents, and immunotherapy. The targeted therapy segment can be further classified as abemaciclib, ado-trastuzumab emtansine, everolimus, trastuzumab, ribociclib, palbociclib, pertuzumab, olaparib category and others. Depending on the kind of cancer, the market has been classified into hormone receptor and HER2+. In the course of the forecast period, the market share of the hormone receptor segment should remain the highest because of a constant increase in the number of patients with breast cancer of this type. The market on the basis of the distribution channel has been classified as the hospital pharmacy; retail pharmacy; online pharmacy; and others. The hospital pharmacies segment is expected to have higher market shares globally because of reliance on such pharmacies in handling treatment regimens like the chemotherapy.
The market size in North America standing at USD 10.34 billion in 2019 had a considerable presence in the global market. It is expected to be the fore lying market in the region in the given forecast period. The growth can be attributed to currently established gigantic companies in the area; this would ensure introduction of new therapeutics in the area . Some of these are like high case density of breast cancer, rising incidence of clinical trials in the development of breast cancer drugs, stepped up earlier use of new generation drugs.
The significant players in the market are Genentech (U.S.), Eli Lilly and Company (U.S.), Novartis AG (Switzerland), AstraZeneca (U.K.), Pfizer Inc. (U.S.), Sanofi (France), Eisai Co. Ltd. (Japan), Kyowa Kirin (Japan), Bristol Myers Squibb (U.S.), Merck & Co., Inc. (U.S.). They are the key player that ensures the industry's success while still having to keep pace with their innovation in product and services. These companies drive the industry's success with their innovations in products and services. Operating globally with diverse product lines, they foster competition, encourage new technologies, and improve quality, helping the market grow and evolve.
In May 2024, Context Therapeutics further enriched its pipeline of breast cancer agent ONA-XR, an oral selective progesterone receptor modulator. This drug is intended for HR positive and HER2 negative breast cancer patients as it works to counter hormone promoting tumor activity. It is still in the phase 1/2 stage and is frequently co-administered with other agents such as elacestrant. ONA-XR acts against the progression of hormone-dependent cancers and is currently under investigation in the advanced and metastatic settings.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2016-2027
Base Year 2019
Forecast Period 2020-2027
Historical Period 2016-2018
Unit Value (USD billion)
Segmentation Therapy, Cancer Type, Distribution Channel, and Geography
By Therapy
Targeted Therapy
Abemaciclib
Ado-Trastuzumab Emtansine
Everolimus
Trastuzumab
Ribociclib
Palbociclib
Pertuzumab
Olaparib
Others
Hormonal Therapy
Selective Estrogen Receptor Modulators (SERMs)
Aromatase Inhibitors
Estrogen Receptor Downregulators (ERDs)
Chemotherapy
Immunotherapy
By Cancer Type
Hormone Receptor
HER2+
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Geography
North America
By Therapy
By Cancer Type
By Distribution Channel
By Country
U.S.
Canada
Europe
By Therapy
By Cancer Type
By Distribution Channel
By Country/ Sub-Region
UK
Germany
France
Italy
Spain
Scandinavia
Rest of Europe
Asia Pacific
By Therapy
By Cancer Type
By Distribution Channel
By Country/ Sub-Region
Japan
China
India
Australia
South East Asia
Rest of Asia Pacific
Latin America
By Therapy
By Cancer Type
By Distribution Channel
By Country/ Sub-Region
Brazil
Mexico
Rest of South America
Middle East & Africa
By Therapy
By Cancer Type
By Distribution Channel
By Country/ Sub-Region
South Africa
GCC Countries
Rest of Middle East & Africa
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence of Breast Cancer, By Key Countries/Regions, 2019
- 4.2. Regulatory Scenario by Key Regions
- 4.3. Overview of Current Advances in R&D for Breast Cancer Therapeutics
- 4.4. Key Industry Developments
- 4.5. New Product Launches
- 5. Global Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Therapy
- 5.2.1. Targeted Therapy
- 5.2.1.1. Abemaciclib
- 5.2.1.2. Ado-Trastuzumab Emtansine
- 5.2.1.3. Everolimus
- 5.2.1.4. Trastuzumab
- 5.2.1.5. Ribociclib
- 5.2.1.6. Palbociclib
- 5.2.1.7. Pertuzumab
- 5.2.1.8. Olaparib
- 5.2.1.9. Others
- 5.2.2. Hormonal Therapy
- 5.2.2.1. Selective Estrogen Receptor Modulators (SERMs)
- 5.2.2.2. Aromatase Inhibitors
- 5.2.2.3. Estrogen Receptor Downregulators (ERDs)
- 5.2.3. Chemotherapy
- 5.2.4. Immunotherapy
- 5.3. Market Analysis, Insights and Forecast – By Cancer Type
- 5.3.1. Hormone Receptor
- 5.3.2. HER+
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Retail Pharmacies
- 5.4.3. Online Pharmacies
- 5.4.4. Others
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis – By Therapy
- 6.2.1. Targeted Therapy
- 6.2.1.1. Abemaciclib
- 6.2.1.2. Ado-Trastuzumab Emtansine
- 6.2.1.3. Everolimus
- 6.2.1.4. Trastuzumab
- 6.2.1.5. Ribociclib
- 6.2.1.6. Palbociclib
- 6.2.1.7. Pertuzumab
- 6.2.1.8. Olaparib
- 6.2.1.9. Others
- 6.2.2. Hormonal Therapy
- 6.2.2.1. Selective Estrogen Receptor Modulators (SERMs)
- 6.2.2.2. Aromatase Inhibitors
- 6.2.2.3. Estrogen Receptor Downregulators (ERDs)
- 6.2.3. Chemotherapy
- 6.2.4. Immunotherapy
- 6.3. Market Analysis – By Cancer Type
- 6.3.1. Hormone Receptor
- 6.3.2. HER+
- 6.4. Market Analysis – By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Retail Pharmacies
- 6.4.3. Online Pharmacies
- 6.4.4. Others
- 6.5. Market Analysis – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
- 7. Europe Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis – By Therapy
- 7.2.1. Targeted Therapy
- 7.2.1.1. Abemaciclib
- 7.2.1.2. Ado-Trastuzumab Emtansine
- 7.2.1.3. Everolimus
- 7.2.1.4. Trastuzumab
- 7.2.1.5. Ribociclib
- 7.2.1.6. Palbociclib
- 7.2.1.7. Pertuzumab
- 7.2.1.8. Olaparib
- 7.2.1.9. Others
- 7.2.2. Hormonal Therapy
- 7.2.2.1. Selective Estrogen Receptor Modulators (SERMs)
- 7.2.2.2. Aromatase Inhibitors
- 7.2.2.3. Estrogen Receptor Downregulators (ERDs)
- 7.2.3. Chemotherapy
- 7.2.4. Immunotherapy
- 7.3. Market Analysis – By Cancer Type
- 7.3.1. Hormone Receptor
- 7.3.2. HER+
- 7.4. Market Analysis – By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Retail Pharmacies
- 7.4.3. Online Pharmacies
- 7.4.4. Others
- 7.5. Market Analysis – By Country/ Sub-Region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
- 8. Asia Pacific Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis – By Therapy
- 8.2.1. Targeted Therapy
- 8.2.1.1. Abemaciclib
- 8.2.1.2. Ado-Trastuzumab Emtansine
- 8.2.1.3. Everolimus
- 8.2.1.4. Trastuzumab
- 8.2.1.5. Ribociclib
- 8.2.1.6. Palbociclib
- 8.2.1.7. Pertuzumab
- 8.2.1.8. Olaparib
- 8.2.1.9. Others
- 8.2.2. Hormonal Therapy
- 8.2.2.1. Selective Estrogen Receptor Modulators (SERMs)
- 8.2.2.2. Aromatase Inhibitors
- 8.2.2.3. Estrogen Receptor Downregulators (ERDs)
- 8.2.3. Chemotherapy
- 8.2.4. Immunotherapy
- 8.3. Market Analysis – By Cancer Type
- 8.3.1. Hormone Receptor
- 8.3.2. HER+
- 8.4. Market Analysis – By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Retail Pharmacies
- 8.4.3. Online Pharmacies
- 8.4.4. Others
- 8.5. Market Analysis – By Country/ Sub-Region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
- 9. Latin America Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis – By Therapy
- 9.2.1. Targeted Therapy
- 9.2.1.1. Abemaciclib
- 9.2.1.2. Ado-Trastuzumab Emtansine
- 9.2.1.3. Everolimus
- 9.2.1.4. Trastuzumab
- 9.2.1.5. Ribociclib
- 9.2.1.6. Palbociclib
- 9.2.1.7. Pertuzumab
- 9.2.1.8. Olaparib
- 9.2.1.9. Others
- 9.2.2. Hormonal Therapy
- 9.2.2.1. Selective Estrogen Receptor Modulators (SERMs)
- 9.2.2.2. Aromatase Inhibitors
- 9.2.2.3. Estrogen Receptor Downregulators (ERDs)
- 9.2.3. Chemotherapy
- 9.2.4. Immunotherapy
- 9.3. Market Analysis – By Cancer Type
- 9.3.1. Hormone Receptor
- 9.3.2. HER+
- 9.4. Market Analysis – By Distribution Channel
- 9.4.1. Hospital Pharmacies
- 9.4.2. Retail Pharmacies
- 9.4.3. Online Pharmacies
- 9.4.4. Others
- 9.5. Market Analysis – By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
- 10. Middle East & Africa Breast Cancer Therapeutics Market Analysis, Insights and Forecast, 2016-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis – By Therapy
- 10.2.1. Targeted Therapy
- 10.2.1.1. Abemaciclib
- 10.2.1.2. Ado-Trastuzumab Emtansine
- 10.2.1.3. Everolimus
- 10.2.1.4. Trastuzumab
- 10.2.1.5. Ribociclib
- 10.2.1.6. Palbociclib
- 10.2.1.7. Pertuzumab
- 10.2.1.8. Olaparib
- 10.2.1.9. Others
- 10.2.2. Hormonal Therapy
- 10.2.2.1. Selective Estrogen Receptor Modulators (SERMs)
- 10.2.2.2. Aromatase Inhibitors
- 10.2.2.3. Estrogen Receptor Downregulators (ERDs)
- 10.2.3. Chemotherapy
- 10.2.4. Immunotherapy
- 10.3. Market Analysis – By Cancer Type
- 10.3.1. Hormone Receptor
- 10.3.2. HER+
- 10.4. Market Analysis – By Distribution Channel
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Online Pharmacies
- 10.4.4. Others
- 10.5. Market Analysis – By Country/ Sub-Region
- 10.5.1. GCC Countries
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2019)
- 11.2. Company Profiles (Overview, Products & Services, SWOT Analysis, Recent Developments, Strategies, Financials (Based On Availability))
- 11.2.1. Genentech (F. Hoffmann-La Roche Ltd)
- 11.2.1.1. Overview,
- 11.2.1.2. Products & Services,
- 11.2.1.3. SWOT Analysis,
- 11.2.1.4. Recent Developments,
- 11.2.1.5. Strategies,
- 11.2.1.6. Financials (Based On Availability)
- 11.2.2. Eli Lilly and Company
- 11.2.2.1. Overview,
- 11.2.2.2. Products & Services,
- 11.2.2.3. SWOT Analysis,
- 11.2.2.4. Recent Developments,
- 11.2.2.5. Strategies,
- 11.2.2.6. Financials (Based On Availability)
- 11.2.3. Novartis AG
- 11.2.3.1. Overview,
- 11.2.3.2. Products & Services,
- 11.2.3.3. SWOT Analysis,
- 11.2.3.4. Recent Developments,
- 11.2.3.5. Strategies,
- 11.2.3.6. Financials (Based On Availability)
- 11.2.4. AstraZeneca
- 11.2.4.1. Overview,
- 11.2.4.2. Products & Services,
- 11.2.4.3. SWOT Analysis,
- 11.2.4.4. Recent Developments,
- 11.2.4.5. Strategies,
- 11.2.4.6. Financials (Based On Availability)
- 11.2.5. Pfizer Inc.
- 11.2.5.1. Overview,
- 11.2.5.2. Products & Services,
- 11.2.5.3. SWOT Analysis,
- 11.2.5.4. Recent Developments,
- 11.2.5.5. Strategies,
- 11.2.5.6. Financials (Based On Availability)
- 11.2.6. Sanofi
- 11.2.6.1. Overview,
- 11.2.6.2. Products & Services,
- 11.2.6.3. SWOT Analysis,
- 11.2.6.4. Recent Developments,
- 11.2.6.5. Strategies,
- 11.2.6.6. Financials (Based On Availability)
- 11.2.7. Eisai Co. Ltd.
- 11.2.7.1. Overview,
- 11.2.7.2. Products & Services,
- 11.2.7.3. SWOT Analysis,
- 11.2.7.4. Recent Developments,
- 11.2.7.5. Strategies,
- 11.2.7.6. Financials (Based On Availability)
- 11.2.8. Kyowa Kirin
- 11.2.8.1. Overview,
- 11.2.8.2. Products & Services,
- 11.2.8.3. SWOT Analysis,
- 11.2.8.4. Recent Developments,
- 11.2.8.5. Strategies,
- 11.2.8.6. Financials (Based On Availability)
- 11.2.9. Bristol Myers Squibb (Celgene Corporation)
- 11.2.9.1. Overview,
- 11.2.9.2. Products & Services,
- 11.2.9.3. SWOT Analysis,
- 11.2.9.4. Recent Developments,
- 11.2.9.5. Strategies,
- 11.2.9.6. Financials (Based On Availability)
- 11.2.10. Merck & Co., Inc.
- 11.2.10.1. Overview,
- 11.2.10.2. Products & Services,
- 11.2.10.3. SWOT Analysis,
- 11.2.10.4. Recent Developments,
- 11.2.10.5. Strategies,
- 11.2.10.6. Financials (Based On Availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook